Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresh Data Pushes Microbiome Pioneer Ferring Closer To Approval Line

RBX2660 Filing Before Year-End

Executive Summary

The promise of microbiome-based therapeutics to treat a variety of diseases has become a hot topic and the first to get to market will be targeting Clostridioides difficile infection. Ferring and its subsidiary Rebiotix are in pole position.

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the ASCO meeting; small biopharma companies thrive in the US; the world’s first positive Phase III data for a microbiome therapy; Adaptimmune’s plans for its T-cell receptor therapy; and Novo looks at semaglutide in early Alzheimer’s.

Stockwatch: The Fall, Rise And Challenges Of Seres' Microbiome Therapy

The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.

Ferring Favorite To Get First Approval For Microbiota-Based Therapy

If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel